- CORRESPONDENCE
By
- Siying Guo1,
- Jun Du2 &
- …
- Ning Li3
-
Yuan Fang
-
Chinese Academy of Medical Sciences–Peking Union Medical College, Beijing, China.
-
-
Siying Guo
-
Chinese Academy of Medical Sciences–Peking Union Medical College, Beijing, China.
-
-
Jun Du
-
Chinese Academy of Medical Sciences–Peking Union Medical College, Beijing, China.
-
-
Ning Li
-
Chinese Academy of Medical Sciences–Peking Union Medical College, Beijing, China.
-
In July, an investigation reported that a six-year-old girl died last year after receiving an experimental brain-directed gene-editing therapy for a rare disorder in Shanghai, China (B. Borrell Science 393, 346–353; 2026). The case pre-dates China’s State Council Order No. 818, a new biomedical technologies framework that came into effect on 1 May. However, the case still highlights the challenges of biomedical regulation.
Nature 657, 312 (2026)
doi: https://doi.org/10.1038/d41586-026-02737-5
Competing Interests
The authors declare no competing interests.
Related Articles
-
Personalized gene editing helped one baby: can it be rolled out widely?
-
New rules spur cell and gene therapy trials in China
-
A society-wide conversation is needed about germline genome editing
-
See more letters to the editor
Subjects
Latest on:
- Gene therapy
- Policy
- Ethics
-
Epigenetic editing makes its mark
Technology Feature
-
Non-genotoxic transplantation and in vivo selection through epitope editing
Article
-
From cloning to gene-editing: the enduring legacy of Dolly the sheep
Editorial
-
The global plastics treaty must account for conflict-driven energy insecurity
Correspondence
-
Europe should adapt, not copy, China’s practical PhD
Correspondence
-
Why are rich people so pessimistic? What the numbers say
Comment
-
Who is responsible when AI helps to write science?
Comment
-
Assessing students in the AI era
Correspondence
-
How tech-enhanced sleep could improve rest but erode privacy
Comment